SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Epicrispr Biotechnologies, a clinical-stage company pioneering gene-modulating therapies, today announced that the first patient has been dosed in its global first-in-human clinical trial of EPI-321, an investigational, one-time epigenetic editing therapy for facioscapulohumeral muscular dystrophy (FSHD). FSHD is a progressive genetic disease...

Join us for The Chris Carrino Foundation Virtual Gala on October 22, 2020!  REGISTER TODAY!